Leflunomid Bluefish (Leflunomide)

Leflunomide blocks the enzyme dihydroorotate dehydrogenase, a key step in making pyrimidine nucleotides. This limits the proliferation of activated lymphocytes, thereby dampening the immune response that drives inflammation in autoimmune joint disorders.

The exact dose of Leflunomid Bluefish is determined by the prescribing clinician based on the patient’s medical condition, response to therapy, and laboratory monitoring. Dosage adjustments are made according to individual safety and efficacy considerations.

Leflunomide is classified as Pregnancy Category X, meaning it is contraindicated in pregnancy because of known teratogenic risk. Women of childbearing potential must use effective contraception, and breastfeeding is not recommended while on therapy.

To request Leflunomid Bluefish, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Compared with conventional DMARDs such as methotrexate, leflunomide offers a once‑daily oral regimen and a distinct mechanism targeting pyrimidine synthesis. It may be used as monotherapy or in combination, but clinicians weigh efficacy, safety profile, and patient tolerance when selecting the most appropriate agent.

Leflunomid Bluefish should be stored at or below 25 °C in its original packaging, protected from moisture and direct sunlight. Do not store in a bathroom or near heat sources to maintain product stability.

The product is taken orally, usually as a tablet, with or without food as directed by the prescriber. Patients should follow the dosing schedule provided by their healthcare professional and not alter the regimen without medical advice.

Serious risks include liver injury, severe infections, and pulmonary toxicity such as interstitial lung disease. Regular monitoring of liver enzymes, blood counts, and respiratory symptoms is essential to detect these adverse events early.

Leflunomide should be avoided in pregnant women, women planning pregnancy, and individuals with severe liver disease, uncontrolled infections, or known hypersensitivity to the drug. Caution is also advised for patients with significant renal impairment.